台灣EGFR突變陽性第IIIA期非小細胞肺癌患者於手術切除後進行Osimertinib輔助治療的成本效益分析

Translated title of the contribution: Cost-Effectiveness Analysis of Adjuvant Osimertinib in Taiwanese Patients with Resected Stage IIIA EGFR-Mutation Positive Non-Small Cell Lung Cancer
  • 陳柏豪

Research output: Types of Thesis › Master's thesis

Translated title of the contributionCost-Effectiveness Analysis of Adjuvant Osimertinib in Taiwanese Patients with Resected Stage IIIA EGFR-Mutation Positive Non-Small Cell Lung Cancer
Original languageChinese (Traditional)
Supervisors/Advisors
  • Cheng, Jur-Shan, Supervisor
StatePublished - 2025
Externally publishedYes

Access to Document

Cite this